Healthcare
Metagenomi, Inc. Common Stock(MGX)
Live Price
Offline$1.17
-2.50% today
1Y Change
-17.81%
Window
Jun 27, 2025 โ Jun 24, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -51.8%
- EPS Growth
- -12.9%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 27, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Metagenomi, Inc. Common Stock (MGX) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $1.17 and down 17.8% across the available one-year price window (Jun 27, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -51.8%, EPS growth of -12.9%, a dividend yield of 0.0%. What stands out right now is revenue -51.8%, EPS -12.9%, free cash flow +20.3% with operating margin -380.9% and ROIC -47.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-51.8% vs +7.6% peer median
Operating Margin
Below sector median
-380.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -51.8% and EPS is at -12.9%, with operating margin around -380.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +2.2% | -7.4% | -8.9% |
2026 Mar 5, 2026 | -3.5% | -8.1% | -2.5% | -16.1% |
2025 Nov 11, 2025 | +8.3% | -15.5% | -22.7% | -17.3% |
Benchmark Edge
MGX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MGX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MGX Max Drawdown
-65.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MGX and SPY.
Company Overview
Metagenomi, Inc. Common Stock
NASDAQ Global Select
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
- Leadership
- Jian Irish
- IPO Date
- Apr 6, 2006
- Employees
- 202
- Street Address
- 5959 Horton Street
- Mailing
- Emeryville, 94608
- Region
- Emeryville, US
- Reporting Currency
- USD
- Investor Line
- 510-871-4880
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.1
- Price/Book
- 0.3
Growth
- Revenue
- -51.8%
- EPS
- -12.9%
- Free Cash Flow
- +20.3%
Profitability
- Gross Margin
- 0.3%
- Operating Margin
- -380.9%
- Net Margin
- -348.5%
- ROE
- -47.1%
- ROIC
- -47.0%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 7.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.